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Autism spectrum disorder (ASD) may arise from
increased ratio of excitatory to inhibitory neurotrans-
mission in the brain. Many pharmacological treat-
ments have been tested in ASD, but only limited
success has been achieved. Here we report that
BTBR T+ Itpr3tf/J (BTBR) mice, a model of idiopathic
autism, have reduced spontaneous GABAergic
neurotransmission. Treatment with low nonsedat-
ing/nonanxiolytic doses of benzodiazepines, which
increase inhibitory neurotransmission through posi-
tive allosteric modulation of postsynaptic GABAA
receptors, improved deficits in social interaction,
repetitive behavior, and spatial learning. Moreover,
negative allosteric modulation of GABAA receptors
impaired social behavior in C57BL/6J and 129SvJ
wild-type mice, suggesting that reduced inhibitory
neurotransmission may contribute to social and
cognitive deficits. The dramatic behavioral improve-
ment after low-dose benzodiazepine treatment was
subunit specific—the a2,3-subunit-selective positive
allosteric modulator L-838,417 was effective, but
the a1-subunit-selective drug zolpidem exacerbated
social deficits. Impaired GABAergic neurotransmis-
sion may contribute to ASD, and a2,3-subunit-selec-
tive positive GABAA receptor modulation may be an
effective treatment.
INTRODUCTION
Autism spectrum disorders (ASDs) are developmental neuropsy-
chiatric diseases with characteristic symptoms of impaired
social interaction, stereotyped behaviors, and delayed language
development (Abrahams and Geschwind, 2008; Geschwind,
2011). One hypothesis is that the core behavioral features of
autism are caused by an imbalance between excitatory and
inhibitory neurotransmission in the brain (Gatto and Broadie,
2010; Markram and Markram, 2010; Rubenstein and Merzenich,
2003). Recent work on mouse models of syndromic autism
caused by monogenic mutations in MeCP2, Scn1a, Shank3,
and Cntnap2 has shown that an increased ratio of excitatory to1282 Neuron 81, 1282–1289, March 19, 2014 ª2014 Elsevier Inc.inhibitory neurotransmission in the brain may cause autistic-
like behaviors (Auerbach et al., 2011; Chao et al., 2010; Han
et al., 2012; Pec¸a et al., 2011; Pen˜agarikano et al., 2011), and
optogenetic increase in excitation/inhibition ratio can also
induce social interaction deficits (Yizhar et al., 2011). The in-
creased ratio of excitatory to inhibitory neurotransmission in
these models may arise by increased excitatory transmission,
decreased inhibitory transmission, or both.
This emerging research implicates increased excitation to
inhibition ratio in causing autistic-like behaviors in monogenic
animal models of autism, but there is much less evidence for
the significance of this mechanism in idiopathic models of
autism. BTBRmice are a well-studiedmodel of idiopathic autism
(Defensor et al., 2011; McFarlane et al., 2008; Yang et al., 2012).
However, the inherited genetic changes that lead to autistic-like
behaviors in these mice are incompletely known and still under
active investigation (Jones-Davis et al., 2013). In the experiments
presented here, we provide evidence from recordings of sponta-
neous synaptic transmission that BTBR mice have a reduced
level of inhibitory neurotransmission mediated by GABAA recep-
tors in the hippocampus compared to the control strain C57BL/
6J, which may contribute to their autistic-like behaviors.
Activation of GABAA receptors by GABA is enhanced by ben-
zodiazepines, which are used in treatment of epilepsy, anxiety,
panic disorder, and insomnia (Rudolph and Knoflach, 2011).
Moreover, genetic linkage of the GABAA receptor to autism
has been widely reported (Li et al., 2012). However, GABAA re-
ceptors have not been recognized as a therapeutic target for
ASDs because of their sedative activity. Our previous studies
showed that low-dose clonazepam was effective in treatment
of impaired social interaction and cognitive deficit in Scn1a+/
mice, a model of Dravet syndrome with marked autistic-like
behaviors (Han et al., 2012).We present evidence here that treat-
ment with low doses of positive allosteric benzodiazepine mod-
ulators of GABAA receptors improves characteristic autistic-like
behaviors in BTBRmice. Interestingly, negative allosteric modu-
lation of GABAA receptors with benzodiazepines induces social
interaction deficits in C57BL/6J and 129SvJ wild-type (WT)
mice, supporting a causal role for reduced inhibitory neuro-
transmission in some features of autism. Moreover, autistic-like
behavioral impairments can be treated effectively in both
BTBR and Scn1a+/ mice by enhancement of inhibitory neuro-
transmission with low doses of subunit-selective positive allo-
steric modulators of GABAA receptors containing a2 and/or a3
subunits. Together, our results support the hypothesis that
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Figure 1. Reduced GABAergic Neurotrans-
mission in BTBR Mice and Enhancement
by Clonazepam
Spontaneous IPSC (sIPSC) and spontaneous
EPSC (sEPSC) were recorded in the hippocampal
slices from 3-week-old male BTBR and C57BL/6J
mice. (A and B) Example traces of sIPSC (A) and
cumulative plot and average values (inset) of
sIPSC frequency in BTBR and C57BL/6J hippo-
campal CA1 neurons (B). (C and D) Example traces
of sEPSC (C) and cumulative plot and average
values (inset) of sEPSC frequency in BTBR and
C57BL/6J hippocampal CA1 neurons (D). (E and F)
Example traces of sIPSC (E) and cumulative plot
and average value (inset) of sIPSC amplitude (F) in
clonazepam- and vehicle-treated BTBR CA1
slices. (G and H) Example traces of sEPSC (G) and
cumulative plot and average value (inset) of sIPSC
frequency (H) in clonazepam- and vehicle-treated
BTBR CA1 slices. CON, control; CLZ, clonaze-
pam. All data shown are represented as means ±
SEM from 15–19 recordings per strain. *p < 0.05,
**p < 0.01, ***p < 0.001.
Neuron
GABA Signaling and Social Behaviorreduced GABAergic inhibitory neurotransmission contributes to
autism-associated behavioral and cognitive deficits and suggest
that enhancement of GABAergic neurotransmission with next-
generation subunit-specific pharmacological agents may be
beneficial.
RESULTS
Reduced Inhibitory Neurotransmission in BTBR Mice
A challenge for research on BTBR mice is selection of an appro-
priate control mouse line for comparison, as different inbred
strains differ in various behavioral and cognitive measures.
Consistent with previous work, we chose to focus our study on
differences in neurotransmission, behavior, and cognition be-
tween BTBR and C57BL/6J mice (see Supplemental Information
available online for more discussion and references). To test the
hypothesis that BTBR mice may have reduced inhibitory neuro-
transmission, we measured spontaneous excitatory and inhibi-
tory postsynaptic currents in the CA1 region of hippocampal
slices from age-matched (postnatal day 21–25 [P21–P25])
BTBR and C57BL/6J mice. Although the amplitude of sponta-
neous inhibitory postsynaptic current (IPSC) was not altered
in BTBR hippocampal slices compared to the C57BL/6J
hippocampal slices (Figure S1A), the frequency of spontaneousNeuron 81, 1282–1289IPSC was significantly reduced in BTBR
hippocampal slices when compared
with the C57BL/6J hippocampal slices
(Figures 1A and 1B). In conjunction with
decreased inhibitory neurotransmission,
the amplitude and the frequency of spon-
taneous excitatory postsynaptic current
(EPSC) were substantially increased in
BTBR hippocampal slices when com-
pared with C57BL/6J hippocampal slices
(Figures 1C, 1D, and S1B). In controlrecordings of miniature postsynaptic currents, in which action
potentials were blocked with tetrodotoxin (TTX), the amplitude
and frequency of miniature IPSC and the frequency of miniature
EPSC were unaltered (Figures S1E–S1G). However, the ampli-
tude of miniature EPSCs was significantly increased in BTBR
hippocampal slices when compared with C57BL/6J hippocam-
pal slices (Figure S1H). Surprisingly, these studies reveal that
BTBR mice have a deficit in inhibitory neurotransmission
compared to the control strain C57BL/6J, which is caused by
reduced frequency of inhibitory synaptic events without a corre-
sponding decrease in postsynaptic response. This deficit in
inhibitory neurotransmission is accompanied by a correspond-
ing increase in excitatory neurotransmission. These results indi-
cate that constitutively decreased inhibitory neurotransmission
may be a contributing factor to the autistic-like behaviors in
BTBR mice.
Increased GABAergic Inhibitory Neurotransmission in
Response to Benzodiazepines
Attempts to reverse autistic-like traits by rebalancing the ratio of
excitatory to inhibitory neurotransmission through pharmacolog-
ical treatments that reduce excitatory neurotransmission have
met with only partial success because of their limited efficacy
and unwanted side effects in control groups (Berry-Kravis, March 19, 2014 ª2014 Elsevier Inc. 1283
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Figure 2. Effects of Low-Dose Clonazepam on Social Interaction
and Cognitive Deficits in BTBR Mice
(A–D) Age-matched male C57BL/6J (n = 6; each group) and BTBR (n = 9; each
group) mice were treated with a single intraperitoneal dose of clonazepam at
the indicated level and subjected to the three-chamber social interaction test.
Testmicewere not reused; different groups ofmicewere used for each dose of
clonazepam treatment. (A and B) Time in chambers for C57BL/6J (A) and
BTBR (B). (C and D) Ratio of time in mouse chamber to time in object chamber
for C57BL/6J (C) and BTBR (D). (E–G) The effects of low-dose clonazepam
(CLZ; 0.05 mg/kg) on open-field activity were measured in C57BL/6J (n = 8)
and BTBR (n = 10) mice: total distance moved (E), circling number (F), and
number of entries into the center of the open field (G). (H) Time in open arms in
elevated plus maze for BTBR mice (n = 10) and C57BL/6J mice (n = 10). (I) In
the three-chamber test, BTBR (blue) and C57BL/6J (black) mice were treated
with vehicle (Pre, Post) or low-dose clonazepam (CLZ) 30 min before testing
social interactions on day 0 (Pre), day 7 (CLZ), or day 14 (Post). The ratio of
interaction time with the stranger mouse or object is plotted. (J and K) In the
open-field reciprocal social interaction test, BTBR (blue) and C57BL/6J (black)
mice were treated with vehicle (Pre, Post) or low-dose clonazepam (CLZ)
30 min before testing social interactions on day 0 (Pre), day 7 (CLZ), or day 14
(Post). The ratio of interaction time with the stranger mouse versus object is
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1284 Neuron 81, 1282–1289, March 19, 2014 ª2014 Elsevier Inc.et al., 2012; Gandal et al., 2012; Henderson et al., 2012;Michalon
et al., 2012; Yang et al., 2012). The results of Figures 1A–1D
suggest that enhancing inhibitory neurotransmission might be
effective. The GABAA receptor is a heteropentameric ligand-
gated chloride channel that mediates the major inhibitory effects
of GABAergic neurotransmission in the brain. Subsynaptic
GABAA receptor subtypes are composed of two a, two b, and
one g subunit (Fritschy and Mohler, 1995). The action of GABA
at these ionotropic receptors is increased through positive allo-
steric modulation by benzodiazepines, which are used to treat
anxiety, insomnia, and epilepsy (Rudolph and Knoflach, 2011).
In order to determine whether treatment with a benzodiazepine
reverses the constitutively decreased GABAergic inhibitory
signaling, we treated C57BL/6J and BTBR hippocampal slices
with 0.5 mM clonazepam, a broad-acting, traditional benzodiaz-
epine. These recordings revealed increased spontaneous IPSC
amplitude (Figures 1E and 1F) and frequency (Figure S1C) in
BTBR slices. In contrast, a significant increase of spontaneous
IPSC amplitude (Figure S1I), but no change in IPSC frequency
(Figure S1J), was observed in C57BL/6J slices. The increased
GABAergic signaling after treatment with clonazepam led to a
decrease in frequency of spontaneous EPSCs (Figures 1G
and 1H), without change in amplitude in BTBR hippocampal
slices (Figure S1D). Interestingly, the frequency of spontaneous
EPSC was also decreased by clonazepam (Figure S1K), without
change in amplitude (Figure S1L) in C57BL/6J slices. These data
support the idea that low-dose clonazepam can reverse the
underlying deficit in spontaneous GABAergic inhibitory neuro-
transmission in BTBR mice.
Improvement of Social Interaction by Treatment with
Clonazepam
To test the behavioral effects of enhancing inhibitory neurotrans-
mission in BTBR mice, we injected low nonsedating/nonanxio-
lytic doses of clonazepam intraperitoneally 30 min prior to
behavioral tests. In the three-chamber social interaction test,
acute clonazepam treatment had no effect on social interactions
of C57BL/6J mice (Figures 2A and S2A) but increased social in-
teractions in BTBR, with a maximal effect at 0.05 mg/kg (Figures
2B and S2B) and no sedation (Figure S2H). Measurements of the
time of interaction of the test mouse with a stranger mouse
versus a novel object during three-chamber tests showed that
the C57BL/6J mice are unaffected by any of the test doses (Fig-
ure 2C), whereas improvement of the social deficit in BTBRmice
by clonazepam is strikingly dose dependent (Figure 2D). Inter-
estingly, the improved social interactions in BTBR mice were
lost at higher doses of clonazepam (Figures 2B and 2D). Otherplotted for BTBRmice (n = 9) or C57BL/6J mice (n = 9) for total interaction time
(J) and nose-to-nose interaction time (K). (L and M) To test tolerance to the
effects of low-dose clonazepam on locomotor and social behaviors, BTBR
mice (n = 10; each group) were treated with low-dose (0.05 mg/kg) and high-
dose (1 mg/kg) clonazepam for 14 days. (L) Total distance moved during the
open-field test after drug treatment on day 1 and day 14 was measured, and
percentage of activity change was calculated by comparing the activity on day
1 and day 14 of treatment with the indicated doses of clonazepam. (M) Social
interaction behavior was compared after treatment with low-dose clonazepam
(n = 10 for each group). CON, control; CLZ, clonazepam. All data shown are
represented as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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epam. In the open-field test, a single injection of 0.05 mg/kg clo-
nazepam significantly reduced hyperactivity, measured as the
total distance moved (Figure 2E), and stereotyped circling
behavior, measured as the number of 360 rotations (Figure 2F).
In contrast, these behaviors in C57BL/6J mice were unaffected
by low-dose clonazepam. These low doses of clonazepam had
little effect on anxiety-like behaviors of C57BL/6J mice, such
as avoidance of the center of an open field or the open arms of
an elevated plus maze (Figures 2G and 2H). However, compared
to C57BL/6J, BTBR mice visited the center in the open field
significantly more frequently and spent more time in open arms
during the elevated plus-maze test under control conditions, as
if they were less anxious than C57BL/6J mice, and these indica-
tors of abnormally low anxiety in BTBR mice were changed
toward the values for C57BL/6J mice after treatment with
0.05 mg/kg clonazepam (Figures 2G and 2H) without sedation
(Figure S2I).
Three sets of identical three-chamber tests at 1-week intervals
with the same group of mice showed the reversibility of rescue of
social interaction deficits in BTBR by 0.05 mg/kg clonazepam
(Figures 2I–2K and S1C–S1F). In the first trial, with no treatment,
BTBR mice displayed characteristic social interaction deficits
when compared with C57BL/6J mice for interaction ratio with a
stranger mouse versus an inanimate object (Figure 2I). In a
second identical trial 1 week later, these social deficits were
improved by treatment with 0.05 mg/kg clonazepam 30 min
before testing in the same group of BTBR mice (Figure 2I). In
the third trial 1 week later, injection of vehicle had no effect to
rescue the social behavior in the same mice (Figure 2I). None
of these treatments had any significant effect on C57BL/6J
mice (Figure 2I). This reversible effect of clonazepam treatment
was also observed in the open-field reciprocal social interaction
test in an intragroup comparison setting in which the test mouse
cannot escape from the social stimulus provided by the stranger
mouse. During three identical sets of reciprocal social interaction
tests, impaired reciprocal social interaction and nose-to-nose
contact in BTBR mice were significantly enhanced in the
0.05 mg/kg clonazepam-treated group, whereas C57BL/6J
mice were unaffected (Figures 2J and 2K). These data show
that low-dose clonazepam increases social interaction in BTBR
mice within a narrow effective dose range.
Long-term treatment with the standard high doses of benzodi-
azepines causes tolerance in humans (Bateson, 2002). Toler-
ance to the sedative effects of high-dose clonazepam begins
on day 7 and reaches maximum on day 14 in mice (Galpern
et al., 1991; Lo¨scher et al., 1996). To test tolerance in this context
in BTBR mice, we injected 0.05 mg/kg clonazepam intraperito-
neally daily for 14 days. For untreated animals, the locomotor
activity in an open field was 68% ± 11% of normal on day 14
compared to day 1 (Figure 2L), probably because the open-field
chamber is familiar from their experience on day 1 and they
do not explore it as extensively on day 14. Treatment with
0.05 mg/kg clonazepam did not have any effect on locomotor
activity and did not alter the ratio of activity on days 1 and 14 (Fig-
ure 2L). In contrast, injection of 1 mg/kg clonazepam for 14 days
caused significant tolerance, as indicated by the large increase
in level of locomotor activity on day 14 compared to day 1 dueto the repeated administration of the drug (222% ± 42%;
Figure 2L). In the three-chamber social interaction test,
0.05 mg/kg clonazepam significantly increased social interac-
tions on day 1, and this effect was fully retained and even
increased after 14 days of repeated treatment (Figure 2M). These
data indicate that repeated treatment with 0.05 mg/kg dose of
clonazepam does not elicit tolerance to its rescue of social inter-
action behavior in the time frame of development of tolerance for
the sedative effects of the drug.
Amelioration of Cognitive Deficits by Treatment with
Clonazepam
Cognitive problems are often associated with ASD (Zoghbi and
Bear, 2012), and BTBR mice are known to have impaired fear
memory (MacPherson et al., 2008). To test the effects of low-
dose clonazepam on cognitive deficits, we performed context-
dependent fear conditioning after treatment with increasing
doses of clonazepam in both BTBR and C57BL/6J mice (Figures
3A and 3B). Short-term (30 min) and long-term (24 hr) memory
performance in fear conditioning to the spatial context in
BTBR mice were improved by treatment with 0.05 mg/kg clo-
nazepam, but no significant effects were observed after treat-
ment with 0.0125 mg/kg or 0.1 mg/kg clonazepam (Figures 3B
and S3B). In contrast, no cognitive changes were observed in
C57BL/6J mice at any dose (Figures 3A and S3A). To test spatial
learning and memory in the absence of fear, we performed the
Barnes circular maze test in which mice rapidly escape a
brightly lit field by learning the location of a hole with a dark
refuge at its periphery. BTBR mice failed to improve their perfor-
mance during repeated training sessions, and this learning
impairment was improved by clonazepam treatment (Figures
3C and 3D). In probe trials, in which mice search for a learned
refuge that has been removed, spatial memory in BTBR mice
was also increased by clonazepam treatment (Figures 3E–3G).
In contrast, C57BL/6J mice displayed improved learning perfor-
mance during repeated training sessions (Figures 3C and 3D),
and normal spatial memory during the probe trial (Figures 3E–
3G), regardless of clonazepam treatment. These data indicate
that spatial learning in BTBR mice is substantially restored by
treatment with low-dose clonazepam.
To determine whether tolerance develops to clonazepam,
we performed context-dependent fear conditioning on day 1
of clonazepam injection and day 14 of daily treatment with
0.05 mg/kg clonazepam. Regardless of the treatment period,
the context-dependent fear memory was improved by clonaze-
pam treatment in BTBR mice (Figures 3H and 3I; Figures S3C
and S3D), suggesting that low-dose clonazepam treatment
does not cause tolerance to its effects on cognitive deficit in
BTBR mice.
Opposing Effects of Positive and Negative Allosteric
Modulators of GABAA Receptors
In order to test the effect of other classes of GABAA receptor
modulators on social behavior, we treated BTBR mice with
low-dose clobazam, an atypical benzodiazepine that is a posi-
tive allosteric modulator of GABAA receptors (Farrell, 1986). A
single injection of 0.05 mg/kg clobazam 30 min before the
three-chamber test ameliorated social interaction deficits inNeuron 81, 1282–1289, March 19, 2014 ª2014 Elsevier Inc. 1285
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Figure 3. Effects of Low-Dose Clonazepam on Context-Dependent
Spatial Learning and Memory Deficits in BTBR Mice
(A and B) Increasing doses (0, 0.0125, 0.05, and 0.1 mg/kg) of clonazepam
were administered 30 min prior to context-dependent fear conditioning. (A)
C57BL/6J (n = 5–7). (B) BTBR (n = 5–7). (C and D) Barnes circular maze. Spatial
learning was measured for C57BL/6J and BTBR mice (n = 10 each) by mea-
surement of the latency (C) and number of errors (D) for mice to find safety
without and with treatment with 0.05 mg/kg clonazepam as indicated. Note
that treatment with clonazepam significantly improved the performance of
BTBRmice but, in contrast, significantly worsened the performance of C57BL/
6J mice. (E–G) On day 5 of the Barnes maze test, a single injection of low-dose
clonazepam was given 30 min prior to the trial for BTBR and C57BL/6J mice:
latency to target (E); percentage of correct pokes (F); percentage of time in
target (G). (H and I) BTBR mice (n = 10) were treated with 0.05 mg/kg clo-
nazepam for 14 days. Contextual fear conditioning was performed 30min after
injection on day 1 (H) and day 14 (I). CON, control; CLZ, clonazepam. All data
shown are represented as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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GABA Signaling and Social BehaviorBTBR mice (Figures 4A and 4B) without sedative (Figure 4C) or
anxiolytic effects (Figure 4D). To further test the idea that the
E/I balance is critical for normal social behaviors, we treated
C57BL/6J and 129SvJ WT mice with low-dose DMCM, a nega-
tive allosteric modulator of the GABAA receptor function as
assessed from inhibitory postsynaptic potentials recorded in
hippocampal slices and from behavioral tests (Rovira and
Ben-Ari, 1993; Savic et al., 2006). In the three-chamber test, a
single injection of a low nonconvulsant/nonanxiogenic dose
of DMCM (0.2 mg/kg) (Savic et al., 2004) 30 min prior to the
test substantially reduced normal social interaction behavior in1286 Neuron 81, 1282–1289, March 19, 2014 ª2014 Elsevier Inc.both C57BL/6J and 129SvJ mice (Figures 4E, 4F, 4M, and
S4A). In contrast, the general locomotor behavior and anxiety
levels were not altered by 0.2 mg/kg DMCM (Figures 4G and
4H). Our results with DMCM support the notion that impairment
of GABAergic neurotransmission might contribute to autistic-like
behaviors.
Rescue by a2,a3-Specific Positive Allosteric Modulators
of GABAA Receptors
Diversity of GABA receptor function is conferred bymore than 20
different subunits, and receptors with different a subunits play
distinct roles in the physiological and pharmacological actions
of GABA and benzodiazepines (Fritschy and Mohler, 1995;
Harmar et al., 2009; Rudolph and Knoflach, 2011; Rudolph and
Mo¨hler, 2004; Smith and Olsen, 1995). We tested the effects of
subunit-selective positive allostericmodulators of GABAA recep-
tors on social behavior in BTBR mice and C57BL/6J mice. A low
dose of the a2,3-subunit-selective positive allosteric modulator
L-838,417 (Lo¨w et al., 2000; Mathiasen et al., 2008) increased
social interactions in BTBR mice, with maximal effective dose
of 0.05 mg/kg, and the beneficial effect was lost when the
dose increased (Figures 4I and S4E). In contrast, L-838,417
did not change the social interaction behavior of C57BL/6J
mice (Figure S4I). Moreover, the a1-subunit-selective positive
GABAA modulator zolpidem (Mathiasen et al., 2008; Sieghart,
1995) failed to show beneficial effects in BTBRmice and actually
aggravated their social interaction deficit at high doses (Figures
4J and S4F). Interestingly, a high dose of zolpidem also impaired
social behavior in C57BL/6J mice (Figure S4J). Total movement
tended to increase at high doses of L-838,417 (Figure S4G; not
significant) but significantly decreased at 0.5 mg/kg zolpidem
(Figure S4H). These results indicate that different subtypes of
GABAA receptors may have opposite roles in social behavior,
with activation of GABAA receptors containing a2,3 subunits
favoring and activation of GABAA receptors with a1 subunits
reducing social interaction, respectively.
Subunit-selective GABAA receptor modulators may also have
an important effect on cognitive behaviors. In the context-
dependent fear conditioning test, treatment with 0.05 mg/kg
L-838,417 improved short-term (30 min) and long-term (24 hr)
spatial memory in BTBR mice (Figure 4K), whereas 0.05 mg/kg
zolpidem enhanced short-termmemory but not long-term mem-
ory (Figure 4L). These data show that a2,3-subunit-containing
GABAA receptors may also be important for cognitive behaviors
in BTBRmice. The bell-shaped dose-response curves observed
for both L-838,417 and clonazepam may explain why high-dose
benzodiazepine treatment for prevention of anxiety and seizures
has not been reported to improve autistic traits in ASD patients.
As illustrated in Figures 4N and 4O, treatment with low doses of
L-838,417 also improves social interactions in the Scn1a+/
mice, a model of Dravet syndrome with severe autistic-like
behaviors (Han et al., 2012), within a narrow dose range. In
contrast, similar treatment with zolpidem is not effective.
Altogether, these experiments show that treatment with an
a2,3-selective positive allosteric modulator of GABAA receptors
is sufficient to rescue autistic-like behaviors and cognitive deficit
in both a monogenic model of autism-spectrum disorder and the
BTBR mouse model of idiopathic autism.
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Figure 4. Effects of Positive and Negative GABAA
Receptor Allosteric Modulators on Social Behav-
iors and Cognitive Deficit
(A and B) Effect of clobazam (CBZ, 0.05 mg/kg) on social
interaction behavior of BTBR mice in the three-chamber
test (n = 7–8). (C and D) Effect of clobazam (0.05 mg/kg) on
BTBRmice (n = 7–8) in the open-field test on total distance
moved (C) and time spent in center (D). (E and F) Effect of
DMCM (0.2 mg/kg) on C57BL/6J mice (n = 7–8) in the
three-chamber test. Time in indicated chamber (E). Ratio
of time spent with mouse/time spent with object (F). (G)
Effect of DMCM (0.2 mg/kg) on overall exploratory
behavior of C57BL/6J mice (n = 8) in the open-field test,
measured as distance moved. (H) Anxiety-like behavior of
C57BL/6J mice (n = 8) in the elevated plus-maze test,
measured as time in the open arms. (I and J) Social inter-
action behavior of BTBR mice (n = 6–8) in the three-
chamber test after treatment with the indicated doses of
L-838,417 (I) or zolpidem (J). Test mice were not reused;
different groups of mice were used for each dose. (K and L)
Contextual fear conditioning test of BTBRmice (n = 5) after
treatment with 0.05mg/kg of L-838,417 (K) or zolpidem (L).
Control data were replotted from Figure 2B. (M) Effect of
DMCM (0.2 mg/kg) on 129SvJ mice (n = 8) in the three-
chamber test. (N and O) Effects of L-838,417 (N) and
zolpidem (O) onScn1a+/mice (n = 8) in the three-chamber
test. CON, control; CBZ, clobazam; CLZ, clonazepam. All
data shown are represented as means ± SEM. *p < 0.05,
**p < 0.01, ***p < 0.001.
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Our results on mouse models of autism support the hypothesis
that social and cognitive deficits in ASDs may be caused by an
increased ratio of excitatory to inhibitory synaptic transmission
(Gatto and Broadie, 2010; Han et al., 2012; Markram and Mark-Neuron 81, 128ram, 2010; Rubenstein and Merzenich, 2003).
We found that autistic BTBR mice have consti-
tutively reduced inhibitory neurotransmission
in the hippocampus and that enhancement of
their inhibitory neurotransmission with positive
allosteric modulators of GABAA receptors
improved autism-related traits. Conversely, we
found that global pharmacological reduction of
inhibitory neurotransmission by the negative
allosteric modulator DMCM was sufficient
to induce some autism-related behaviors in
C57BL/6J and 129SvJ WT mice. These results
are most consistent with the hypotheses that
reduced inhibitory neurotransmission is suffi-
cient to induce autistic-like behaviors in mice
and that enhanced inhibitory neurotransmission
can reverse autistic-like behaviors. However,
even though the BTBR mouse has been widely
used as an animal model of autism, it is not
yet fully understood which genetic changes
lead to its autistic-like behaviors (Jones-Davis
et al., 2013) or whether similar genetic changes
are among the large number of DNA polymor-
phisms that have been implicated in humanautism. Similarly, even though treatment of C57BL/6J mice
and 129SvJ mice with a negative allosteric modulator of
GABA receptors, DMCM, induces specific autism-related
behavioral impairments in these two mouse strains, it is not
known whether this would be true for all mouse strains or
whether decreasing the effectiveness of GABAergic inhibitory2–1289, March 19, 2014 ª2014 Elsevier Inc. 1287
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GABA Signaling and Social Behaviorneurotransmission with DMCM or a related agent would cause
any of the behavioral features of human autism.
GABAA receptors with different subunit composition have
different roles in synaptic transmission in hippocampal pyrami-
dal neurons. Receptors containing a1 subunits mediate fast syn-
aptic transmission at the synapses on distal dendrites, whereas
receptors containing a2 subunitsmediate fast synaptic transmis-
sion at synapses on the soma (Prenosil et al., 2006). Different in-
puts impinge on CA1 pyramidal neurons at these sites, providing
a potential mechanism for understanding how specific modula-
tion of these two receptor types with L-838,417 and zolpidem
leads to differential effects on spatial learning and sedation.
Because GABAA receptors containing a2 subunits have specific
physiological roles (Prenosil et al., 2006) and drug actions on
them do not induce tolerance (Vinkers et al., 2012), they provide
an attractivemolecular target for therapy of autism and other dis-
orders with reduced GABAergic inhibitory neurotransmission.
Therapeutic approaches to treat autistic traits in animal studies
or in clinical trials have primarily focused on reducing excitatory
neurotransmission in glutamatergic synapses to rebalance E/I
ratio in autistic brain (Michalon et al., 2012; Yang et al., 2012).
However, autistic-like behaviors in ASD mouse models are only
partially reversed by drugs that inhibit excitatory neurotransmis-
sion, and these drugs also have unwanted side effects on wild-
type mice (Henderson et al., 2012; Michalon et al., 2012; Yang
et al., 2012). To overcome these drawbacks, we focused on the
opposing side, the GABAergic inhibitory transmission in autistic
brain. Our results highlight the potential for therapy of autistic-
like behaviors and cognitive deficit in ASDby low-dose treatment
with subunit-selective benzodiazepines and other positive allo-
steric modulators of GABAA receptors. At low doses that do not
induce sedative or anxiolytic effects, we found that clonazepam,
clobazam, andL-838,417all improvedautistic-like behaviors and
cognitive deficit in BTBR mice, supporting the hypothesis that
a2,3-subunit-selective upregulation of GABAergic neurotrans-
mission could be an effective treatment for these core features
of autism. Consistent with this conclusion, the a1-subunit-selec-
tive positive allosteric modulator zolpidem had opposite effects.
It is possible that the biphasic dose-response relationship of the
positive allosteric modulators reflects their actions on receptors
containinga2,3 subunits at lowdosesandon receptors containing
a1 subunits at higher doses.
Although tolerance develops during prolonged treatment of
patients with high doses of traditional benzodiazepines, our
experiments indicate that tolerance is not induced by treatment
of mice with low doses of clonazepam for 14 days, and a2,3-
selective positive allosteric modulators of GABAA receptors do
not induce tolerance in rodents (Vinkers et al., 2012). Because
of their broad availability and safety, benzodiazepines and other
positive allosteric modulators of GABAA receptors administered
at low nonsedating, nonanxiolytic doses that do not induce
tolerance deserve consideration as a near-term strategy to
improve the core social interaction deficits and repetitive behav-
iors in ASD. Consistent with this view, Astra-Zeneca and the
National Institutes of Health have initiated clinical trials of the
a2,3-selective positive allosteric modulator of GABAA receptors,
AZD7325, for efficacy in autism (http://clinicaltrials.gov/show/
NCT01966679).1288 Neuron 81, 1282–1289, March 19, 2014 ª2014 Elsevier Inc.EXPERIMENTAL PROCEDURES
Adult male mice 6–10 months old were used for all behavioral tests. All mice
were singly housed at least 1 week before the behavioral tests. All experiments
with animals were performed according to the National Institutes of Health
Guide for Care and Use of Laboratory Animals and were approved by the Uni-
versity ofWashington Institutional Animal Care andUse Committee. The open-
field test, elevated plus-maze test, three-chamber test, reciprocal interaction
test, Barnes circular maze test, and contextual fear conditioning test were car-
ried out asdescribed previously (Han et al., 2012) and inSupplemental Informa-
tion. As required for stable recordings of spontaneous synaptic activity, brain
slices from 3- to 4-week-old mice were used for electrophysiological studies,
which were carried out as described previously (Han et al., 2012). Drugs
were administered and data were analyzed as described previously (Han
et al., 2012) and in Supplemental Information. All data are shown as mean ±
SEM and analyzed using Student’s t test, one-way ANOVA with Tukey’s post
hoc comparison, and two-way ANOVAwith Bonferroni’s post hoc comparison.
All the statistical analyses were done using Prism 6 (GraphPad).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.neuron.2014.01.016.
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